Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now

Fresenius Medical Care AG & Co. FMS entered 2026 with improving profitability, accelerating execution of its transformation strategy and growing momentum in HighVolumeHDF and value-based care. However, persistent treatment volume weakness, looming reimbursement headwinds, regulatory pressure in China and inflation-related cost risks continue to pose meaningful challenges to the company's long-term growth outlook.

Shares of this Zacks Rank #3 (Hold) company have declined 4.9% so far this year compared with the industry’s 8.9% decline. However, the S&P 500 Index has gained 10.8% over the same time frame.

FMS, with a market capitalization of $12.21 billion, is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. Its bottom line is anticipated to improve 2.4% over the next five years. FMS delivered an average earnings surprise of 7.39% for the trailing four quarters.

Image Source: Zacks Investment Research

Factors Driving FMS’ Prospects

FME25+ Transformation Is Structurally Improving Profitability: Fresenius Medical Care’s FME25+ transformation program is increasingly translating into sustainable earnings gains. The company delivered EUR 67 million of sustainable savings in the second quarter, while group operating income rose 23% at constant currency and operating margin expanded 180 basis points.

In Care Delivery, underlying operating income, excluding TDAPA effects, increased 34%, supported by clinic closures, higher rates and revenue-cycle improvements. Management expects continued margin expansion across the business, suggesting that cost optimization is becoming a structural earnings lever rather than a one-time benefit. This should provide a cushion against volume and reimbursement pressures while supporting the company’s medium-term profitability targets.

5008X and High-Volume HDF Could Drive Meaningful Growth: The accelerating rollout of the 5008X dialysis system and high-volume hemodiafiltration (HDF) represents an important long-term growth catalyst.

By late July, FMS had upgraded to 5008X in 227 U.S. clinics across 23 states, representing 10% of its machine base. Since launch, it has conducted more than 600,000 treatments using 5008X. Early clinical experience is encouraging, including reports of fewer muscle cramps and high-volume HDF adoption across research cohorts.

The company is also generating real-world evidence through the BEACON-US initiative. As adoption expands, HDF could improve patient outcomes, strengthen FMS’ clinical differentiation and eventually support higher equipment and consumables demand.

Value-Based Care Is Emerging as a Key Growth and Profitability Driver: FMS’ Value-Based Care business is showing a meaningful improvement in both scale and profitability. Segment revenues increased 9% organically and at constant currency, driven by higher member months and favorable premium rates, while operating income improved to EUR 18 million from a EUR 9 million loss a year earlier.

The 500-basis-point margin improvement and stronger savings rate indicate that contracting capabilities and clinical management are gaining traction. Management also reduced its 2026 revenue guidance for the segment to EUR 150-200 million from the previously expected EUR 300 million. Continued contracting growth and better patient outcomes could therefore make Value-Based Care an increasingly important contributor to earnings.

Strong Care Delivery Execution Provides an Earnings Buffer: Despite weaker U.S. treatment volumes, FMS’ Care Delivery business demonstrated substantial operating leverage. Revenues grew 7% organically, supported by favorable rate development, TDAPA reimbursement and revenue-cycle management initiatives, while operating income surged 45% and margin expanded 390 basis points.

Profitability improved even after accounting for lower treatment volumes, indicating that pricing, yield management and restructuring actions are offsetting some volume weakness. The company also completed its clinic-footprint optimization, exiting around 100 underperforming clinics, with management citing favorable rates and operational benefits. If these initiatives continue to improve utilization and cost efficiency, Care Delivery can sustain stronger earnings even before U.S. patient volumes fully recover.

Key Challenges

U.S. Treatment Volumes and Referrals Remain the Biggest Operational Risk: FMS’ U.S. same-market treatment growth declined 0.9% in the second quarter, reflecting an operational failure to capture its fair share of patient referrals. Management acknowledged that conditions deteriorated in May and June and that the referral issue was more significant than initially anticipated.

Organizational changes have been implemented, but management expects the recovery to take several quarters and now forecasts 2026 U.S. same-market treatment growth at around the second-quarter level.

The problem is particularly important because dialysis economics depend heavily on treatment volumes and clinic utilization. Although patient mortality and missed treatments improved, prolonged weakness in referral capture could limit revenue growth and force further capacity adjustments if volumes fail to recover.

TDAPA Benefits Are Reversing Into a Substantial Earnings Headwind: FMS faces a significant second-half earnings comparison as temporary benefits from the Transitional Drug Add-on Payment Adjustment (TDAPA) reverse. The company generated roughly EUR 80 million of year-over-year TDAPA benefit in the second quarter, but expects the overall 2026 contribution to become a EUR 50 million year-over-year headwind.

For phosphate binders specifically, a roughly EUR 70 million positive impact in the first half is expected to become a EUR 120 million headwind in the second half. Consequently, FMS anticipates negative earnings growth in the second half despite improving underlying profitability. The TDAPA roll-off also remains a major uncertainty for 2027, complicating earnings comparisons and potentially limiting near-term valuation upside.

China Regulatory Pressure Is Weighing on Care Enablement: Care Enablement remains exposed to regulatory and tender-related pressure in China, limiting an otherwise healthier underlying business. The segment delivered only 3% organic revenue growth, while earnings declined 5%, with management citing regulatory measures, stricter tender requirements, inflation and logistics costs.

China created approximately a EUR 20 million headwind in the second quarter, although management expects the impact to normalize during the second half and remain below EUR 50 million for the full year. The broader concern is that continued regulatory intervention could constrain pricing, market access and product volumes in an important medical-products market. Until the company’s refreshed China strategy gains traction, Care Enablement growth is likely to remain uneven.

Inflation, Reimbursement and ACA Disruption Could Constrain Growth: FMS continues to face several external pressures that could offset operational gains. Elevated raw-material and logistics costs, partly linked to the Middle East conflict, are already weighing on Care Enablement and require mitigation through FME25+ savings.

In the United States, the expiration of ACA subsidies is expected to create an approximately $50 million full-year headwind, with some patients leaving exchange plans because of affordability. The preliminary U.S. reimbursement bundle rate indication of 1% remains below inflation, creating potential pressure on future rate growth. These factors could limit revenue growth and increase reliance on productivity improvements to sustain margins.

Fresenius Medical Care AG & Co. KGaA Price and Consensus

Fresenius Medical Care AG & Co. KGaA price-consensus-chart | Fresenius Medical Care AG & Co. KGaA Quote

Estimate Trend

The Zacks Consensus Estimate for 2026 revenues is pegged at $22.77 billion, indicating 2.7% year-over-year growth. The consensus mark for earnings is pinned at $2.25 per share, implying a decline of 7% from the year-ago level.

Stocks to Consider

Some better-ranked stocks from the broader medical space are Globus Medical GMED, Veracyte VCYT and West Pharmaceutical WST.

Globus Medical, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Veracyte, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.

VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.

West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research